Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 4,118 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Primary Hyperoxaluria Type 1 (PH1)
Interventions: ABO-101; Drug
Lead sponsor: Arbor Biotechnologies; Industry
Eligibility: 6 Years to 64 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2043
U.S. locations: 2
States / cities: Rochester, Minnesota • Saint Paul, Minnesota

Conditions: Suicidal Ideation, Suicide Attempt
Interventions: Brief skills sessions plus EMI skills practice prompts, Ecological momentary assessment (EMA), Treatment as usual (TAU); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Plaque Psoriasis
Interventions: 188-0551 Spray, RLD; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Scottsdale, Arizona • Thousand Oaks, California • Miami, Florida

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: IW-1973, Placebo Oral Tablet; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 45 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 57
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 45 more

Conditions: HIV Infections
Interventions: Intermitent Dosing; Drug
Lead sponsor: Community Research Initiative of New England; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 3 more

Conditions: Visual Acuity
Interventions: senofilcon A Multifocal, senofilcon A Sphere, etafilcon A Multifocal, etafilcon A Sphere; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 6
States / cities: Orlando, Florida • East Lansing, Michigan • Raytown, Missouri + 3 more

Conditions: HIV Negative, Adaptive Immunity, Innate Immunity
Interventions: VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer), Cancer, Colon Cancer, Rectal Cancer, Lung Cancer, CRC, Head and Neck Squamous Cell Cancer, HNSCC, Renal Cell Carcinoma, RCC, Kidney Cancer, Triple Negative Breast Cancer, TNBC, Colorectal Adenocarcinoma
Interventions: A2B395, xT CDx with HLA-LOH assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 10
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 7 more

Conditions: Multiple Myeloma
Interventions: recombinant interferon alfa, carmustine, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, prednisone, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 70 Years
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2006
U.S. locations: 34
States / cities: Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 25 more

Conditions: Chemotherapy-induced Thrombocytopenia
Interventions: Avatrombopag, Placebo Oral Tablet; Drug
Lead sponsor: Sobi, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 14
States / cities: Anaheim, California • Bakersfield, California • Riverside, California + 11 more

Conditions: Fatty Liver
Interventions: Polyunsaturated fatty acid (Opti-EPA), Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Diabetes, Diabetic Foot Ulcer, Non-healing Wound
Interventions: ExpressGraft-C9T1 Skin Tissue; Biological
Lead sponsor: Stratatech, a Mallinckrodt Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Phoenix, Arizona • Fresno, California • San Francisco, California + 1 more

Conditions: Diet, Healthy, Diet Habit, Disease, Chronic, Health Behavior, Rural Health
Interventions: The UnProcessed Pantry Project (UP3); Behavioral
Lead sponsor: Montana State University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Healthy
Interventions: PRA023, Placebo; Drug · Other
Lead sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Multiple Myeloma
Interventions: 89Zr-daratumumab PET/CT; Drug
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Irvine, California • Miami, Florida

Conditions: Cervical Cancer, HIV
Interventions: DeepDOF Images; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 25 Years to 49 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK189075, pioglitazone, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 14
States / cities: Mesa, Arizona • Hollywood, Florida • Miami, Florida + 9 more

Conditions: Acute Appendicitis
Interventions: Sulfur hexafluoride lipid-type A microspheres; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years to 17 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Melanoma
Interventions: Single agent, adjuvant anti-PD1 therapy; Drug
Lead sponsor: John Kirkwood; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Scar Tissue, Hypertrophic Scar, Hypertrophic Scar of Upper Arm (Disorder), Hypertrophic Surgical Scar, Dry Needling
Interventions: True dry needling, Sham dry needling; Other
Lead sponsor: Iran University of Medical Sciences; Other
Eligibility: 20 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Diseases, Heart Diseases
Interventions: Physical activity, Wellness; Behavioral
Lead sponsor: HealthPartners Institute; Other
Eligibility: Up to 100 Years
Enrollment: 448 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Acne
Interventions: Acne mRNA vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 79
States / cities: Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more

Conditions: Healthy
Interventions: Endotoxin, Placebo; Biological · Other
Lead sponsor: Robert J Noveck, M.D.; Other
Eligibility: 18 Years to 40 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Dihydrotestosterone, Periprosthetic Joint Infection (PJI), Cutibacterium Acnes
Interventions: Finasteride 5 mg, Placebo Control; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)

Real-time Intervention for Suicide Risk Reduction

A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population

Immune Responses to Two Experimental HIV Vaccines in Healthy Adults

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers

Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver

Multiple Applications of ExpressGraft-C9T1 Skin Tissue as a Treatment for Diabetic Foot Ulcers

The UnProcessed Pantry Project (UP3)

A Study of PRA023 in Healthy Volunteers

A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

Evaluation of a Novel Optical Microscope With a Deep Depth of Field (DeepDOF) to Provide Histologic-quality Images on Cervical Biopsies and Loop Electrosurgical Excision Procedure (LEEP) Specimens at the Point-of-care

Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)

The Role of Contrast Enhanced Ultrasound in Appendicitis

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Effectiveness of Dry Needling in Linear Scar Tissue

Examining Psychosocial Mediators of Exercise Behavior

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans

Finasteride and Cutibacterium